[A17-33] Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2017
Project no.:
A17-33
Commission:
Commission awarded on 21.07.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Type 2 diabetes mellitus
Due to a lack of data, an added benefit is not proven for the combination with other drugs except insulin and sulfonylureas
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-43 | Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-12 | Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-16 | Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |